Nalbuphin Amomed (Nalbuphine Hydrochloride)

Nalbuphine activates kappa opioid receptors to produce analgesia while blocking mu opioid receptors, which reduces typical mu‑mediated effects such as respiratory depression, providing effective pain relief with a distinct safety profile.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s condition, pain severity, route of administration, and individual response.

Safety data for nalbuphine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Unlike pure mu‑agonist opioids such as morphine, nalbuphine’s mixed agonist‑antagonist profile offers analgesia with a lower risk of respiratory depression and reduced potential for dependence, making it a useful alternative in patients where these concerns are prominent.

Nalbuphin Amomed should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the product, and ensure it remains within the recommended temperature range during transport.

The product is supplied as a sterile injectable solution and can be given intramuscularly, intravenously, or subcutaneously by a qualified healthcare professional, following aseptic technique and appropriate dosing guidelines.

Serious risks include respiratory depression, severe hypotension, allergic reactions such as anaphylaxis, and, in rare cases, profound constipation or paralytic ileus. Prompt monitoring and supportive care are essential if these events occur.

Patients with known hypersensitivity to nalbuphine or any formulation component, those taking MAO inhibitors, or individuals with severe respiratory compromise should avoid using this medication unless a specialist determines that benefits outweigh risks.